MGX Metagenomi Inc. Total Business Assets

Official company branding of Metagenomi Therapeutics (MGX)

International conflicts and sanctions hinder Metagenomi, Inc. (MGX) from accessing global genetic archives, slowing biomedical research. The absence of commercial products leaves the company dependent on external investments, with total assets amounting to 223.00. The market price reflected in this chart demonstrates the potential of this biotech firm, which is developing ultra-precise DNA modification tools based on unique microbial libraries for the therapy of complex pathologies.

Metagenomi (MGX) Aggregate Company Assets: for the period 02/21/2024 - 10/31/2026

Comprehensive metric breakdowns and analytics for Metagenomi, Inc (MGX)

- stock quotes and analyst forecast:
Share Price metagenomi.co|MGX - Price Target Chart
- market capitalization data:
Market Capitalization Metagenomi Therapeutics|MGX - Enterprise Value
- book capitalization information:
Book Value per Share Metagenomi|MGX - Company Book Value|Market Cap to Net Assets Ratio metagenomi.co|MGX - Company Total Assets
- debt burden and liquidity indicators:
Debt to Capital Metagenomi, Inc.|MGX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Metagenomi Therapeutics|MGX - Company Aggregate Debts|Debts to Book Capitalization Metagenomi Therapeutics|MGX - Company Long-Term Debts|Short-Term Indebtedness Metagenomi|Immediate Liquidity metagenomi.co
- earnings and market multiples details:
MGX - Company Net Income
Fundamental valuation:Metagenomi, Inc.
Signature product of Metagenomi Inc.

Seeking to redefine gene editing precision standards through metagenomics, Metagenomi (MGX) requires significant resources to develop innovative CRISPR tools. An analysis of total assets, reverse-calculated via ROA and reaching a value of 223.00, allows for an assessment of the company's aggregate capital and liabilities, which for this class of venture securities serves as an indicator of financial stability and the scale of its technological potential.

Direct competitors

Total Business Assets TEM|Aggregate Company Assets Qiagen|Total Business Assets IONS (Ionis Pharmaceuticals, Inc.)|Company Total Assets RGEN|Company Total Assets Avidity Corp (RNA)|Aggregate Company Assets CRISPR Therapeutics AG CRSP|WGS - Cumulative Company Assets|Ultragenyx - Company Total Assets|Company Assets Beam Therapeutics Inc|SRPT (Sarepta Therapeutics Inc) - Cumulative Company Assets|TWST: Aggregate Business Assets|TXG (10x Genomics, Inc.) - Company Total Assets|Company Total Assets intelliatx.com|Company Total Assets STOK|BioLife Solutions Inc (BLFS) - Company Balance Sheet Assets|Company Total Assets WVE (Wave Life Sciences Corp)|Maze Therapeutics Corp (MAZE) - Company Assets|SION - Aggregate Company Assets|PRME (primemedicine.com) - Total Business Assets|Taysha Gene Therapies, Inc. (TSHA) - Aggregate Company Assets|Company Assets uniQure NV (QURE)|Aggregate Company Assets MeiraGTx PLC|Cumulative Company Assets REGENXBIO Corp (RGNX)|Company Total Assets SLDB|Company Total Asset Base ocugen.com|PacBio - Cumulative Company Assets|Aggregate Asset Value BNTC|Design Pharma - Company Total Assets|Company Total Asset Base Rocket Corp RCKT|4D Molecular Therapeutics (FDMT) - Aggregate Company Assets|Total Business Assets LXEO|KRRO (Korro Bio Inc.) - Company Total Assets|Cumulative Company Assets Editas Medicine Inc (EDIT)|Cumulative Company Assets SLN (Silence Therapeutics Inc.)|Company Total Asset Base proqr.com|Aggregate Company Assets Codexis CDXS|SGMO - Cumulative Company Assets|Nautilus Biotechnology Inc - Company Total Assets|Company Balance Sheet Assets precisionbiosciences.com (DTIL)|GBIO (generationbio.com) - Cumulative Company Assets|Total Business Assets BOLD|XCUR (Exicure Inc.) - Company Total Assets|Total Business Assets IMNN (Celsion Corporation)|Aggregate Company Assets Phio Pharmaceuticals (PHIO)|mustangbio.com - Total Business Assets|Company Total Assets RNAZ (TransCode Therapeutics, Inc.)|Company Total Assets Bionano Genomics Inc. BNGO|APDN - Aggregate Company Assets|bluebirdbio.com (BLUE) - Cumulative Company Assets|IPA: Company Total Assets|Company Assets Omega Therapeutics Inc (OMGA)|Cumulative Company Assets OMIC|RGLS (Regulus) - Aggregate Business Assets|Company Total Assets SYRS|Company Total Assets telesisbio.com (TBIO)|Company Total Assets TCON (TRACON Pharmaceuticals, Inc.)|Company Balance Sheet Assets Unity Biotechnology Inc.